{
  "author": {
    "name": "Cynthia Koons",
    "webUrl": "/author/profile/cynthia-koons/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 25,
    "social": [],
    "articles": [
      {
        "uri": "/2019/11/04/havens-amazon-jpmorgan-roll-out-new-health-plans/",
        "title": "Haven's Amazon, JPMorgan roll out new health plans",
        "byline": "Michelle F. Davis, Cynthia Koons and Matt Day",
        "kicker": "News",
        "prettyDate": "November 04, 2019",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/06/amazon2-1.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/michelle-f-davis-cynthia-koons/",
            "name": "Michelle F. Davis, Cynthia Koons"
          },
          {
            "webUrl": "/author/profile/matt-day/",
            "name": "Matt Day"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The efforts appear to be early steps in the venture's goal of overhauling health-care benefits to make them more transparent.",
        "body": null
      },
      {
        "uri": "/2019/04/12/drugmakers-cave-on-insulin-prices-why-now/",
        "title": "Drugmakers cave on insulin prices. Why now?",
        "byline": "Cynthia Koons and Anna Edney",
        "kicker": "News",
        "prettyDate": "April 12, 2019",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/11/Diabetic.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          },
          {
            "webUrl": "/author/profile/anna-edney/",
            "name": "Anna Edney"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The actions have raised questions about why it took public pressure before the companies altered their programs.",
        "body": null
      },
      {
        "uri": "/2019/02/21/civica-rxs-plan-to-reform-pharma-collaborate-not-compete/",
        "title": "Civica Rx's plan to reform pharma: Collaborate, not compete",
        "byline": "Cynthia Koons",
        "kicker": "News",
        "prettyDate": "February 21, 2019",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/03/RisingHealthCosts.jpg",
          "width": "600",
          "height": "385"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Rather than manufacture its own drugs, Civica Rx will act as a go-between for hospitals and drugmakers to pool demand and increase supply.",
        "body": null
      },
      {
        "uri": "/2019/01/16/drugmakers-vs-trump-whats-next-for-the-showdown/",
        "title": "Drugmakers vs. Trump: What's next for the showdown?",
        "byline": "Kristen V Brown, Cynthia Koons, Anna Edney, and Riley Griffin",
        "kicker": "Market Insights",
        "prettyDate": "January 16, 2019",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/02/DrugCosts2.jpg",
          "width": "600",
          "height": "401"
        },
        "authors": [
          {
            "webUrl": "/author/profile/kristen-v-brown-cynthia-koons-anna-edney/",
            "name": "Kristen V Brown, Cynthia Koons, Anna Edney,"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "The Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. Will it work?",
        "body": null
      },
      {
        "uri": "/2019/01/09/eli-lilly-says-no-to-tv-list-prices-but-offers-a-compromise/",
        "title": "Eli Lilly says 'no' to TV list prices but offers a compromise",
        "byline": "Cynthia Koons",
        "kicker": "News",
        "prettyDate": "January 09, 2019",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/05/DrugPricesShadow.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The drugmaker will start airing television ads touting the website lillypricinginfo.com, along with a toll-free telephone number.",
        "body": null
      },
      {
        "uri": "/2018/10/16/pharma-balks-at-proposal-to-list-drug-prices-in-tv/",
        "title": "Pharma balks at proposal to list drug prices in TV ads",
        "byline": "Cynthia Koons and Anna Edney",
        "kicker": "News",
        "prettyDate": "October 16, 2018",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/10/PharmaReceipt.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          },
          {
            "webUrl": "/author/profile/anna-edney/",
            "name": "Anna Edney"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Drugmakers have said that disclosing list prices without additional context would be confusing to patients.",
        "body": null
      },
      {
        "uri": "/2018/08/10/generic-drugmakers-struggle-to-stay-afloat/",
        "title": "Generic drugmakers struggle to stay afloat",
        "byline": "Cynthia Koons",
        "kicker": "Market Insights",
        "prettyDate": "August 10, 2018",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/05/MoneyVsPills.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Many widely used copycat medications are seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water.",
        "body": null
      },
      {
        "uri": "/2018/04/18/generic-drug-makers-feeling-the-squeeze/",
        "title": "Generic drug makers feeling the squeeze",
        "byline": "Cynthia Koons",
        "kicker": "Market Insights",
        "prettyDate": "April 18, 2018",
        "timeToRead": "8 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/Drugs.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons/",
            "name": "Cynthia Koons"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Generic drugs account for more than 90 percent of U.S. prescriptions. Overcapacity and the emergence of big purchasing groups have slammed manufacturers' margins.",
        "body": null
      },
      {
        "uri": "/2017/10/26/bribery-charges-brought-against-opioid-manufacture/",
        "title": "Bribery charges brought against opioid manufacturer",
        "byline": " Cynthia Koons, Jef Feeley ",
        "kicker": "",
        "prettyDate": "October 26, 2017",
        "timeToRead": "3 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/cynthia-koons-jef-feeley/",
            "name": "Cynthia Koons, Jef Feeley"
          }
        ],
        "kickerNode": [],
        "summary": "Insys Therapeutics Inc. founder John Kapoor is accused of helping fuel the U.S. opioid epidemic by bribing doctors to prescribe a powerful form of fentanyl to patients who didnt need the potent drug.",
        "body": null
      },
      {
        "uri": "/2016/08/30/mylan-fails-to-stop-epipen-firestorm-as-senators-s/",
        "title": "Mylan fails to stop EpiPen firestorm as senators seek answers",
        "byline": " Anna Edney, Cynthia Koons ",
        "kicker": "",
        "prettyDate": "August 30, 2016",
        "timeToRead": "5 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/anna-edney-cynthia-koons/",
            "name": "Anna Edney, Cynthia Koons"
          }
        ],
        "kickerNode": [],
        "summary": "20 senators have sent a letter expressing serious concerns regarding the latest uptick in price for Mylan's EpiPen.",
        "body": null
      }
    ]
  }
}